Premium
The expression and localization of melanoma inhibitory activity (MIA) and its functional role in breast cancer
Author(s) -
Clarke Pamela Agatha Georgia,
Deonauth Kamla Barbara,
Eckberg William Robert
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.lb64-a
Subject(s) - skbr3 , western blot , melanoma , breast cancer , immunofluorescence , cancer research , cancer , cell culture , immunohistochemistry , biology , blot , metastatic breast cancer , pathology , metastasis , medicine , antibody , immunology , human breast , gene , biochemistry , genetics
Melanoma Inhibitory Activity (MIA) is a small, secreted protein normally expressed in chondrocytes and appears to be a pivotal player in their differentiation. Initially identified as a tumor suppressor, MIA is now a major metastatic marker for melanoma and has been identified as a key molecule in melanoma tumor progression. Melanoma patients expressing high levels of serum MIA have a poor prognosis and exhibit a reduced response to various chemotherapeutic agents. This observation prompted us to look for a correlation between MIA levels and metastatic potential in breast cancer cell lines. The cell lines chosen ranged from minimally to highly metastatic. We examined the expression and localization of MIA by western blot, RT‐PCR and immunofluorescence. Western blot and RT‐PCR detected MIA in the MDA‐MB 435, MDA‐MB 231, MCF‐7, SKBR3, T‐47 D and SKMEL5 (melanoma control) cell lines. RT‐PCR and western blot analysis revealed relatively high MIA mRNA and protein levels respectively in MDA MB 435 and MDA MB 231, the two most metastatic cell lines. MIA was detected as diffuse staining throughout the cytoplasm of the breast cancer cells. Analyses of preliminary data suggest a positive correlation between MIA expression and tumor progression in these cell lines as in melanoma and some other cancer cells. Hence, MIA has the potential of being a predictive marker for patients’ outcomes in breast cancer. Supported by: NSF HRD‐0401697